Board-Driven Partnerships InVivo has added biotech veterans to its board, signaling a strategic push toward partnerships, licensing, and co-development. Engage the board and leadership to explore collaborations that extend the RapidGen platform into neurology, metabolism, and rare diseases.

AI and Automation Fit The NIH Fast-Track SBIR grant for AI-based zebrafish monitoring signals a strong emphasis on automation and data analytics. Propose AI powered imaging, data integration with their lab workflows, and scalable analytics to boost reproducibility and throughput in preclinical studies.

Platform Expansion Potential RapidGen enables multimodal in vivo screening; there is opportunity to offer complementary services such as omics data analysis, CRISPR tooling, assay development, and data pipelines that seamlessly integrate with their platform.

Funding and Preclinical Demand With a strong preclinical focus and external funding, InVivo may pursue collaborations that accelerate programs and de-risk studies. Propose funded pilots, joint development projects, or grant aligned workflows to co-create value.

Small Team Flexible Partnership Lean operations suggest InVivo favors flexible, low-friction collaborations and scalable outsourcing. Position as a preferred partner for rapid, modular enhancements to RapidGen through modular instrumentation, analytics, or CRO services.